Brown Brothers Harriman & Co’s BridgeBio Pharma BBIO Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1K	Hold	162	–	–	﹤0.01%	1392
2026 Q1	$12K	Buy	162 +21	+15%	+$1.52K	﹤0.01%	1321
2025 Q4	$10.8K	Buy	+141	New	+$9.26K	﹤0.01%	1328
2022 Q2	–	Sell	-3,600	Closed	-$37K	–	1304
2022 Q1	$37K	Hold	3,600	–	–	﹤0.01%	832
2021 Q4	$60K	Hold	3,600	–	–	﹤0.01%	676
2021 Q3	$169K	Hold	3,600	–	–	﹤0.01%	483
2021 Q2	$219K	Hold	3,600	–	–	﹤0.01%	420
2021 Q1	$222K	Sell	3,600 -400	-10%	-$26.2K	﹤0.01%	396
2020 Q4	$284K	Buy	+4,000	New	+$193K	﹤0.01%	381

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Brown Brothers Harriman & Co's BBIO Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 162 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

Brown Brothers Harriman & Co first reported a position in BBIO in Q4 2020 and has held it in 9 quarters since. The position peaked at $284K in Q4 2020. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Brown Brothers Harriman & Co held 162 shares of BridgeBio Pharma worth $12.1K as of Q2 2026.
Brown Brothers Harriman & Co left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1392 holding.
Brown Brothers Harriman & Co first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 9 quarters since.
Brown Brothers Harriman & Co's BridgeBio Pharma position peaked at $284K in Q4 2020.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.